T. Rowe Price Investment Management’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $20.6M | Buy |
716,172
+26,907
| +4% | +$774K | 0.01% | 496 |
|
|
2025
Q1 | $23.1M | Sell |
689,265
-313,617
| -31% | -$10.5M | 0.02% | 499 |
|
|
2024
Q4 | $51.3M | Sell |
1,002,882
-65,650
| -6% | -$3.36M | 0.03% | 404 |
|
|
2024
Q3 | $54.6M | Sell |
1,068,532
-278,678
| -21% | -$14.2M | 0.03% | 394 |
|
|
2024
Q2 | $60.3M | Sell |
1,347,210
-1,307,519
| -49% | -$58.6M | 0.04% | 367 |
|
|
2024
Q1 | $124M | Buy |
2,654,729
+237,236
| +10% | +$11.1M | 0.08% | 256 |
|
|
2023
Q4 | $86M | Buy |
2,417,493
+776,801
| +47% | +$27.6M | 0.06% | 301 |
|
|
2023
Q3 | $48.8M | Buy |
1,640,692
+676,687
| +70% | +$20.1M | 0.03% | 367 |
|
|
2023
Q2 | $17.4M | Buy |
964,005
+34,636
| +4% | +$624K | 0.01% | 490 |
|
|
2023
Q1 | $14.9M | Buy |
+929,369
| New | +$14.9M | 0.01% | 492 |
|